BIOMAT Database Logo BIOMAT Database Logo

Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies. 2005

Kyriaki Avgidou, and Aris Papageorghiou, and Renu Bindra, and Kevin Spencer, and Kypros H Nicolaides
Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, London, UK.

OBJECTIVE This study was undertaken to evaluate the performance of a 1-stop clinic for first-trimester assessment of risk (OSCAR) for trisomy 21 by a combination of maternal age, fetal nuchal translucency (NT) thickness, and maternal serum-free ss- human chorionic gonadotrophin (hCG) and pregnancy-associated plasma protein-A (PAPP-A). METHODS OSCAR was carried out in 30,564 pregnancies at 11 to 13 + 6 weeks. Patient-specific risks for trisomy 21 and detection and false-positive rates were calculated. RESULTS The median maternal age was 34 (range 15-49) years. Chromosomal abnormalities were identified in 330 pregnancies, including 196 cases of trisomy 21. The estimated risk for trisomy 21 was 1 in 300 or greater in 7.5% of the normal pregnancies, in 93.4% of those with trisomy 21 and in 88.8% of those with other chromosomal defects. CONCLUSIONS The most effective method of screening for chromosomal defects is by first-trimester fetal NT and maternal serum biochemistry.

UI MeSH Term Description Entries
D008131 London The capital of the United Kingdom. It is located in England.
D008423 Maternal Age The age of the mother in PREGNANCY. Age, Maternal,Ages, Maternal,Maternal Ages
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009333 Neck The part of a human or animal body connecting the HEAD to the rest of the body. Necks
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011261 Pregnancy Trimester, First The beginning third of a human PREGNANCY, from the first day of the last normal menstrual period (MENSTRUATION) through the completion of 14 weeks (98 days) of gestation. Early Placental Phase,Pregnancy, First Trimester,Trimester, First,Early Placental Phases,First Pregnancy Trimester,First Pregnancy Trimesters,First Trimester,First Trimester Pregnancies,First Trimester Pregnancy,First Trimesters,Phase, Early Placental,Phases, Early Placental,Placental Phase, Early,Placental Phases, Early,Pregnancies, First Trimester,Pregnancy Trimesters, First,Trimesters, First
D011266 Pregnancy-Associated Plasma Protein-A A product of the PLACENTA, and DECIDUA, secreted into the maternal circulation during PREGNANCY. It has been identified as an IGF binding protein (IGFBP)-4 protease that proteolyzes IGFBP-4 and thus increases IGF bioavailability. It is found also in human FIBROBLASTS, ovarian FOLLICULAR FLUID, and GRANULOSA CELLS. The enzyme is a heterotetramer of about 500-kDa. PAPP-A,IGFBP-4 Metalloproteinase,IGFBP-4 Protease,IGFBP-4-Specific Proteinase,Insulin-Like Growth Factor-Dependent IGF Binding Protein-4 Protease,Insulin-Like-Growth Factor Binding Protein-4 Protease,PAPP-alpha,Pregnancy Associated alpha Plasma Protein,Pregnancy-Associated alpha-Plasma Protein,IGFBP 4 Metalloproteinase,IGFBP 4 Protease,Insulin Like Growth Factor Binding Protein 4 Protease,Insulin Like Growth Factor Dependent IGF Binding Protein 4 Protease,Metalloproteinase, IGFBP-4,PAPP alpha,Pregnancy Associated Plasma Protein A,Protease, IGFBP-4
D011296 Prenatal Diagnosis Determination of the nature of a pathological condition or disease in the postimplantation EMBRYO; FETUS; or pregnant female before birth. Diagnosis, Prenatal,Fetal Diagnosis,Fetal Imaging,Fetal Screening,Intrauterine Diagnosis,Antenatal Diagnosis,Antenatal Screening,Diagnosis, Antenatal,Diagnosis, Intrauterine,Prenatal Screening,Antenatal Diagnoses,Antenatal Screenings,Diagnosis, Fetal,Fetal Diagnoses,Fetal Imagings,Fetal Screenings,Imaging, Fetal,Intrauterine Diagnoses,Prenatal Diagnoses,Prenatal Screenings,Screening, Antenatal,Screening, Fetal,Screening, Prenatal
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective

Related Publications

Kyriaki Avgidou, and Aris Papageorghiou, and Renu Bindra, and Kevin Spencer, and Kypros H Nicolaides
Performance of first trimester screening for Trisomy 21 in twin pregnancies.
January 2021, Prenatal diagnosis,
Kyriaki Avgidou, and Aris Papageorghiou, and Renu Bindra, and Kevin Spencer, and Kypros H Nicolaides
Prospective validation of first-trimester combined screening for trisomy 21.
July 2009, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology,
Kyriaki Avgidou, and Aris Papageorghiou, and Renu Bindra, and Kevin Spencer, and Kypros H Nicolaides
First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction.
July 2001, Human reproduction (Oxford, England),
Kyriaki Avgidou, and Aris Papageorghiou, and Renu Bindra, and Kevin Spencer, and Kypros H Nicolaides
First trimester biochemical screening for trisomy 21.
September 1995, Annals of clinical biochemistry,
Kyriaki Avgidou, and Aris Papageorghiou, and Renu Bindra, and Kevin Spencer, and Kypros H Nicolaides
First-trimester screening for trisomy 21 with adjustment for biochemical results of previous pregnancies.
January 2011, Fetal diagnosis and therapy,
Kyriaki Avgidou, and Aris Papageorghiou, and Renu Bindra, and Kevin Spencer, and Kypros H Nicolaides
Nasal bone in first-trimester screening for trisomy 21.
July 2006, American journal of obstetrics and gynecology,
Kyriaki Avgidou, and Aris Papageorghiou, and Renu Bindra, and Kevin Spencer, and Kypros H Nicolaides
First-trimester screening for trisomy 21 using alpha-fetoprotein.
January 2011, Fetal diagnosis and therapy,
Kyriaki Avgidou, and Aris Papageorghiou, and Renu Bindra, and Kevin Spencer, and Kypros H Nicolaides
Second-trimester genetic sonography after first-trimester combined screening for trisomy 21.
March 2009, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine,
Kyriaki Avgidou, and Aris Papageorghiou, and Renu Bindra, and Kevin Spencer, and Kypros H Nicolaides
First trimester maternal serum placental growth factor in trisomy 21 pregnancies.
May 2010, Prenatal diagnosis,
Kyriaki Avgidou, and Aris Papageorghiou, and Renu Bindra, and Kevin Spencer, and Kypros H Nicolaides
Second trimester screening for trisomy 21.
July 1989, Lancet (London, England),
Copied contents to your clipboard!